Sartans Market Report 2026

The sartans market size has grown steadily in recent years. It will grow from $22.18 billion in 2025 to $23.09 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to high global hypertension prevalence, cardiovascular disease burden, generic drug adoption, hospital-based prescribing, long-term safety profile of sartans.

The sartans market size is expected to see steady growth in the next few years. It will grow to $27.14 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to aging population, rising kidney disease incidence, demand for cost-effective therapies, outpatient treatment expansion, growth of digital pharmacies. Major trends in the forecast period include increasing use in hypertension management, growth of generic angiotensin receptor blockers, preference for combination cardiovascular therapy, expansion of online pharmacy distribution, focus on renal and cardiovascular protection.

The rising prevalence of hypertension is expected to drive the growth of the sartans market in the coming years. Hypertension is a condition characterized by persistently high blood pressure, increasing the risk of heart disease, stroke, and other serious health complications. Its growing incidence is largely associated with diets high in salt and processed foods, which cause fluid retention and place additional strain on the heart. Sartans manage hypertension by blocking angiotensin II, a hormone that constricts blood vessels. This action relaxes and widens the vessels, lowers blood pressure, and reduces the heart’s workload. For example, in September 2025, the World Health Organization, a Switzerland-based international public health agency, reported that approximately 1.4 billion adults aged 30-79 worldwide were living with hypertension in 2024, representing about 33% of the global population. Therefore, the rising prevalence of hypertension is boosting the sartans market.

Major companies operating in the sartans market are focusing on developing advanced products, such as tablet-form sartans, to improve treatment effectiveness and patient adherence. Tablet-form sartans are oral medications that block the effects of angiotensin II, promoting vessel relaxation and reducing blood pressure. For instance, in July 2024, Zydus Lifesciences, an India-based pharmaceutical company, received US FDA approval for Valsartan Tablets USP (40 mg, 80 mg), marketed under the brand name Diovan. These tablets are prescribed for hypertension, heart failure, and to improve survival after heart attack in adults, and are also approved for pediatric patients aged one year and older.

In April 2025, Scienture Holdings, Inc., a US-based sartan manufacturer, partnered with Saptalis Pharmaceuticals to produce Arbli (losartan potassium oral suspension, 10 mg/mL). The collaboration includes warehousing and distribution agreements with strategic partners to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in hypertension treatment. Saptalis Pharmaceuticals is a US-based pharmaceutical company.

Major companies operating in the sartans market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co. Inc.

North America was the largest region in the sartans market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sartans market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sartans market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the sartans market by increasing the cost of imported APIs and pharmaceutical intermediates used in antihypertensive drug manufacturing. These impacts are most pronounced in generic drug manufacturing hubs across Asia Pacific and Europe, where large scale production relies on cross border sourcing. Rising tariff related expenses have pressured pricing structures and procurement margins for manufacturers and distributors. This has influenced sourcing strategies and competitive dynamics in both domestic and export markets. However, tariffs have encouraged domestic API production, localized sourcing initiatives, and strengthened long term supply chain resilience.

The sartans market research report is one of a series of new reports that provides sartans market statistics, including sartans industry global market size, regional shares, competitors with a sartans market share, detailed sartans market segments, market trends and opportunities, and any further data you may need to thrive in the sartans industry. This sartans market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sartans, also known as angiotensin II receptor blockers (ARBs), are medications commonly used to treat high blood pressure (hypertension) and heart failure. They work by blocking the effects of angiotensin II, a hormone that constricts blood vessels, thereby promoting vessel relaxation, lowering blood pressure, and improving circulation. Sartans also help reduce the risk of strokes, kidney damage, and heart attacks in patients with certain cardiovascular conditions.

The main types of sartans include valsartan, telmisartan, losartan, irbesartan, azilsartan, and olmesartan. Valsartan is an angiotensin II receptor blocker that lowers blood pressure and decreases cardiac strain by relaxing blood vessels. These medications are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are used for applications such as hypertension, cardiovascular diseases, kidney diseases, and more. End users include hospitals, diagnostic laboratories, and other healthcare facilities.

The sartans market consists of sales of candesartan, eprosartan, and fimasartan. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.